Biocept, Inc.

NasdaqCM:BIOC Voorraadrapport

Marktkapitalisatie: US$2.7m

Biocept Beheer

Beheer criteriumcontroles 3/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Antonino Morales

Algemeen directeur

US$781.6k

Totale compensatie

Percentage CEO-salaris46.8%
Dienstverband CEOless than a year
Eigendom CEOn/a
Management gemiddelde ambtstermijn3.9yrs
Gemiddelde ambtstermijn bestuur6.1yrs

Recente managementupdates

Recent updates

Biocept, Inc. (NASDAQ:BIOC) Shares Fly 48% But Investors Aren't Buying For Growth

Apr 17
Biocept, Inc. (NASDAQ:BIOC) Shares Fly 48% But Investors Aren't Buying For Growth

Statutory Earnings May Not Be The Best Way To Understand Biocept's (NASDAQ:BIOC) True Position

Nov 23
Statutory Earnings May Not Be The Best Way To Understand Biocept's (NASDAQ:BIOC) True Position

Just In: One Analyst Has Become A Lot More Bullish On Biocept, Inc.'s (NASDAQ:BIOC) Earnings

Aug 19
Just In: One Analyst Has Become A Lot More Bullish On Biocept, Inc.'s (NASDAQ:BIOC) Earnings

Shareholders Will Probably Hold Off On Increasing Biocept, Inc.'s (NASDAQ:BIOC) CEO Compensation For The Time Being

Jul 03
Shareholders Will Probably Hold Off On Increasing Biocept, Inc.'s (NASDAQ:BIOC) CEO Compensation For The Time Being

Biocept and CLEARED4 ink collaboration agreement

Jun 09

Biocept enters COVID-19 testing partnership

Apr 28

Biocept (NASDAQ:BIOC) Shareholders Have Enjoyed An Impressive 104% Share Price Gain

Mar 13
Biocept (NASDAQ:BIOC) Shareholders Have Enjoyed An Impressive 104% Share Price Gain

We're Keeping An Eye On Biocept's (NASDAQ:BIOC) Cash Burn Rate

Jan 26
We're Keeping An Eye On Biocept's (NASDAQ:BIOC) Cash Burn Rate

Biocept, Inc. (NASDAQ:BIOC): Is Breakeven Near?

Dec 22
Biocept, Inc. (NASDAQ:BIOC): Is Breakeven Near?

Biocept's assays viable and sensitive for detecting tumor cells and biomarkers

Nov 20

Biocept +4% on COVID-19 testing update

Nov 12

Analyse CEO-vergoeding

Hoe is Antonino Morales's beloning veranderd ten opzichte van Biocept's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2023n/an/a

-US$31m

Mar 31 2023n/an/a

-US$37m

Dec 31 2022US$782kUS$366k

-US$32m

Sep 30 2022n/an/a

-US$25m

Jun 30 2022n/an/a

-US$16m

Mar 31 2022n/an/a

-US$8m

Dec 31 2021US$57kn/a

-US$3m

Compensatie versus markt: De totale vergoeding ($USD 781.63K ) Antonino } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 652.28K ).

Compensatie versus inkomsten: De vergoeding van Antonino is gestegen terwijl het bedrijf verliesgevend is.


CEO

Antonino Morales (67 yo)

less than a year

Tenure

US$781,631

Compensatie

Mr. Antonino Morales serves as Director of Biocept, Inc., since July 20, 2021 and served as its Interim Chief Financial Officer since February 15, 2022 until June 21, 2023 and serves as its Chief Executive...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Antonino Morales
CEO, President & Directorless than a yearUS$781.63kgeen gegevens
Darrell Taylor
Chief Legal Officer1.7yrsUS$773.28k0%
$ 0
Soon Hahn
Founder26.8yrsgeen gegevensgeen gegevens
Rob Walsh
VP & Controllerless than a yeargeen gegevensgeen gegevens
Philippe Marchand
Chief Operating Officer1.6yrsgeen gegevensgeen gegevens
Pavel Tsinberg
Director of Technology Development6.1yrsgeen gegevensgeen gegevens
David Moskowitz
Vice President of Strategy & Corporate Communications7yrsgeen gegevensgeen gegevens
Veena Singh
Senior Medical Director8.8yrsUS$577.58kgeen gegevens

3.9yrs

Gemiddelde duur

59yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van BIOC wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.9 jaar).


Bestuursleden

NaamPositieTenureCompensatieEigendom
Antonino Morales
CEO, President & Director2.3yrsUS$781.63kgeen gegevens
Ivor Royston
Independent Director13.8yrsUS$65.21k0.000080%
$ 2.1
Linda Rubinstein
Independent Director2.3yrsUS$57.26k0%
$ 0
Quyen Dao-Haddock
Independent Directorless than a yearUS$13.32k0%
$ 0
Marsha Chandler
Independent Vice Chairman of the Board9.9yrsUS$70.21k0.000040%
$ 1.1
Fred Hirsch
Member of Clinical Advisory Boardno datageen gegevensgeen gegevens
Bruce Gerhardt
Independent Chairman of the Board13yrsUS$67.71k0.00057%
$ 15.3

6.1yrs

Gemiddelde duur

72yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van BIOC wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.1 jaar).